- [2 - [2 - [2 - [2] methyl] benzene [2 - [2 - [2 - [2 - [2] benzene [1.2.4] triazole [1, 5-a] pyridine-6-il [phenyl] monohydrystal propane, as its own compound, is a method for preparing the dihydrocrystalline compound, 2. Pharmaceutical synthesis and compounds containing such crystalline anhydrous compounds, and the use of such crystalline anhydrous compounds in the treatment or prevention of cancer,In particular, pancreatic cancer, glyceromas, ovarian cancer, non-small cell lung cancer, breast cancer and / or gastric cancer. 1. Claim 1: 4-acrylonitrile (2R) - 2 - (4-fluorophenyl) - N - [4 - (2 - ([2-methoxy-4 - (methylthio) phenyl) amine} [1.2.4] trinitrobenzene [1.5-A] pyridine-6-il] phenyl] acrylohydrazide, characterized by a peak value of XRPD [2q] (copper (Cu)) of about 5.4, 15.6, 16.5, 20 and 24.4. 1. Claim 3: 4-O (2R) - 2 - (4-fluorophenyl) - N - [4 - (2 - [2-methoxy-4 - (methylthio) phenyl] amine} [1,2,4] trinitrosulfonate [1,5-a] pyridine-6-il] phenyl] monocrystalline hydrate；Its characteristic is that its XRPD [2q] (copper) peak is about 5.7, 13.9, 15.8, 18.2 and 18.4.La presente solicitud se refiere a el 4-toluensulfonato de (2R)-2-(4-fluorofenil)-N-[4-(2-{[2-metoxi-4-(metilsulfonil)-fenil]-amino}[1,2,4]triazolo[1,5-a]piridin-6-il)fenil]propan-amida anhidro cristalino y 4-toluensulfonato de (2R)-2-(4-fluorofenil)-N-[4(2-{[2-metoxi-4-(metilsulfonil)fenil]amino}[1,2,4]triazolo[1,5-a]piridin-6-il)fenil]propanamida monohidrato cristalino, como compuestos per se, un método de preparación de dicho compuesto anhidro cristalino, composiciones farmacéuticas y combinaciones farmacéuticas que comprenden dicho compuesto anhidro cristalino y usos de dicho compuesto anhidro cristalino en el tratamiento o la prevención de un cáncer, en particular cáncer de páncreas, glioblastoma, cáncer de ovario, carcinoma de pulmón de células no pequeñas, cáncer de mama, y/o cáncer gástrico. Reivindicación 1: 4-toluensulfonato de (2R)-2-(4-fluorofenil)-N-[4-(2-([2-metoxi-4-(metilsul
